Full Text View
Tabular View
No Study Results Posted
Related Studies
Intravenous Administration of Metoprolol Versus Biatrial Pacing in the Prevention of Atrial Fibrillation After Cardiac Surgery
This study is currently recruiting participants.
Verified by Kuopio University Hospital, August 2009
First Received: October 31, 2008   Last Updated: August 10, 2009   History of Changes
Sponsor: Kuopio University Hospital
Collaborators: Oulu University Hospital
Hospital Cordia, Kuopio, Finalnd
Information provided by: Kuopio University Hospital
ClinicalTrials.gov Identifier: NCT00783900
  Purpose

The aim of the study is to compare the effectiviness of biatrial pacing versus intravenous administration of metoprolol in the prevention of atrial fibrillation after cardiac surgery


Condition Intervention Phase
Atrial Fibrillation
Biatrial Pacing
Metoprolol
Other: metoprolol, biatrial pacing
Phase IV

Study Type: Interventional
Study Design: Prevention, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study
Official Title: Intravenous Metoprolol Versus Biatrial Pacing in the Prevention of Atrial Fibrillation After Cardiac Surgery

Resource links provided by NLM:


Further study details as provided by Kuopio University Hospital:

Primary Outcome Measures:
  • biatriac pacing [ Time Frame: 48 hours ] [ Designated as safety issue: No ]
  • Incidence of atrial fibrillation [ Time Frame: 48 hours ] [ Designated as safety issue: No ]

Estimated Enrollment: 316
Study Start Date: January 2007
Estimated Study Completion Date: June 2010
Estimated Primary Completion Date: December 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
metoprolol: Active Comparator Other: metoprolol, biatrial pacing
Prevention, atrial fibrillation, cardiac surgery, biatrial pacing, metoprolol
biatrial pacing: Active Comparator Other: metoprolol, biatrial pacing
Prevention, atrial fibrillation, cardiac surgery, biatrial pacing, metoprolol

  Eligibility

Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • elective CABG and aortic valve cardiac patients,
  • previous use of beta blocker

Exclusion Criteria:

  • Previous episodes of Atrial fibrillation or flutter,
  • II or II degree atrioventricular block, uncontrolled heart failure
  • Sick sinus syndrome
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00783900

Contacts
Contact: Jari Halonen, MD +358405885829 jari.halonen@kuh.fi
Contact: Martin Maaroos, MD martin.maaroos@cordia.fi

Locations
Finland
Halonen Jari Recruiting
Kuopio, Finland, FIN-70211
Contact: Jari Halonen, MD     +358405885829     jari.halonen@kuh.fi    
Principal Investigator: Jari Halonen, MD            
Sponsors and Collaborators
Kuopio University Hospital
Oulu University Hospital
Hospital Cordia, Kuopio, Finalnd
  More Information

No publications provided

Responsible Party: Kuopio university hospital ( Halonen Jari )
Study ID Numbers: KUH5204006, Eudra-CT: 2008-006932-36
Study First Received: October 31, 2008
Last Updated: August 10, 2009
ClinicalTrials.gov Identifier: NCT00783900     History of Changes
Health Authority: Finland: Finnish Medicines Agency;   Finland: Researc Ethics Committee, Hospital District of Northern Savo

Keywords provided by Kuopio University Hospital:
Prevention

Additional relevant MeSH terms:
Sympatholytics
Neurotransmitter Agents
Heart Diseases
Adrenergic Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs
Cardiovascular Agents
Antihypertensive Agents
Metoprolol
Pharmacologic Actions
Pathologic Processes
Autonomic Agents
Therapeutic Uses
Metoprolol succinate
Adrenergic beta-Antagonists
Cardiovascular Diseases
Adrenergic Antagonists
Peripheral Nervous System Agents
Anti-Arrhythmia Agents
Atrial Fibrillation
Arrhythmias, Cardiac

ClinicalTrials.gov processed this record on February 08, 2010